Participate in a Brain Cancer Clinical Trial

Now Recruiting Patients with Recurrent Glioblastoma

Trial Information

The purpose of the ReSPECT-GBM Clinical Trial is to assess the safety, tolerability, and distribution of a new medication, rhenium (186Re) obisbemeda, in adults with recurrent glioblastoma after standard surgical, radiation, and/or chemotherapy treatment. ReSPECT-GBM is supported by the U.S. National Institutes of Health / National Cancer Institute.

View Trial on



When speaking with your physician, please have the national trial reference number available.



Patients Treated to Date

Single Group

  • All patients who enroll in the trial will receive medication while on the study.
  • All patients will receive a single treatment of rhenium (186Re) obisbemeda.

Phase 1/2

  • Phase 1:  A Phase 1 study of a new medication is usually the first that involves human volunteers who have the disease or condition the investigational medicine is designed to treat.  The primary objective of Phase 1 studies is to identify the highest dose of the new medication that can be safely given without serious side effects.
  • Phase 2:  If a new medication is found to be reasonably safe in a Phase 1 study, it can then be evaluated in a Phase 2 study to determine if it works.  Doctors will assess whether the new medication provides a specific benefit or response, such as tumor shrinkage, improved quality of life, or longer patient survival.


  • Actual Study Start:  June 3, 2015
  • Estimated Primary Completion:  January 2025 (the date that the last participant in a clinical study was examined or received an intervention and that data for the primary outcome measure were collected)
  • Estimated Study Completion:  January 2025 (the date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events, that is, the last participant’s last visit). 

Plus Therapeutics is evaluating rhenium (186Re) obisbemeda, a novel radiotherapy for brain cancer patients, in the U.S. NIH-supported ReSPECT-GBM Phase 2 clinical trial.

Watch now to learn more.

Patient Eligibility

Only a qualified healthcare professional can determine whether or not you are eligible to participate in a clinical trial. However, this information may be beneficial in initiating a conversation with your physician. Patient reimbursement of up to $599 for time and travel is available. Healthy volunteers are not needed.


Recurrent Glioblastoma

Age Range

Adults, 18 Years and Older




Able to undergo a MRI scan

Prior Medication

Have not taken Avastin (bevacizumab)

Principal Investigators

There is a physician who is responsible for the scientific and technical direction of the clinical trial at each location.

Andrew Brenner, M.D., Ph.D.

UT Health San Antonio
Mays Cancer Center


A specialist in both breast cancer and malignancies of the brain and spinal cord, Andrew Brenner, M.D., Ph.D., not only focuses on clinical management, but also on the development of novel therapies to treat breast cancers and central nervous system tumors.

A graduate of Texas A&M University, he earned his bachelor’s degree in biochemistry and went on to earn his doctorate in biological science and tumor biology at The University of Texas M.D. Anderson Cancer Center – Science Park. His doctoral thesis focused on the role of the cyclin dependent kinase inhibitor p16INK4a in mammary tumorigenesis and immortilization. Dr. Brenner’s current interests have transitioned from cell cycle to the effect of hypoxia on chemokines and escape from antiangiogenics and the role of obesity in promoting breast tumorigenesis.

Dr. Brenner received his medical degree from the Texas Tech University Health Science Center and completed a residency in internal medicine at Scott and White Hospital in Lubbock. He completed his fellowship in hematology and medical oncology at the UT Health San Antonio.

Toral Patel, M.D.

UT Southwestern Medical Center
Peter O’Donnell Jr. Brain Institute


Toral Patel, M.D., is an Assistant Professor in UT Southwestern Medical Center’s nationally ranked Department of Neurological Surgery, where she specializes in brain tumor surgery.

Dr. Patel received her undergraduate degree in biomedical engineering from Johns Hopkins University and earned her medical degree at UT Southwestern Medical School. She completed an internship in general surgery at Yale-New Haven Hospital, followed by a residency in neurological surgery, serving as Chief Resident. She then received advanced training in neurosurgical oncology through a fellowship at Memorial Sloan Kettering Cancer Center before returning to UT Southwestern as a faculty member in 2014.

Dr. Patel’s research has garnered numerous awards, including the William F. Collins Resident Research Award, a Seed Grant from the American Medical Association, the UT Southwestern Medical Student Summer Research Award, the Louis E. Goodman Award, and the Johns Hopkins University Department of Biomedical Engineering Undergraduate Research Award. She currently holds a patent titled “Highly penetrative nanocarriers for treatment of CNS disease” for her research into how nanoparticles can be used to carry drugs directly to the site of brain tumors.

Dr. Patel is a member of the Society for Neuro-Oncology, the American Medical Association, the American College of Surgeons, the Congress of Neurological Surgeons, and the American Association of Neurological Surgeons.

She was included in D Magazine‘s Best Doctors list for 2018.

Jeffrey Weinberg, M.D.

UT MD Anderson Cancer Center
Anne C. Brooks Brain and Spine Center


Dr. Jeffrey Weinberg is currently a Professor of Neurosurgery, Deputy Chair and Vice-Chair of Clinical Operations in The Department of Neurosurgery at The University of Texas MD Anderson Cancer Center in Houston, Texas. He is also the Director of the Intraoperative MRI Program.

Dr. Weinberg is a leader in the field of the Neurosurgical Oncology with particular knowledge about intraoperative MRI and technical expertise in surgical management of primary and metastatic brain tumors, spinal cord tumors and stereotactic radiosurgery. He has received various honors which include Excellence in Research Mentorship from the University of Texas Center for Biomedical Engineering, Houston, TX; the Excellence in Teaching Award from the University of Texas Center for Biomedical Engineering for three consecutive years, Top Doctor’s Designation by Castle Connolly and US News and World Report and most recently the MD Anderson Physician Referral Service Sam Hassenbusch Leadership and Institutional Service Award.

Dr. Weinberg is the Chair of the Peri-operative Value Analysis Team; President of the Intraoperative Imaging Society; past President of the Texas Association of Neurological Surgeons; Website Chair for the Joint Tumor Section of the AANS and CNS.

He has published more than 100 manuscripts in peer-reviewed journals and has authored 8 book chapters.

Trial Locations

There are currently 3 clinical trial locations in the United States that are actively screening and enrolling patients.

Please visit this website regularly for updates as new locations are added.

UT Health Science Center

San Antonio

UT Southwestern Medical Center


UT MD Anderson Cancer Center


What Can You Do Next?

Participating in a clinical trial is an important decision. If you believe this clinical trial might be a good fit and are interested in participating, please take the next step to see if you are eligible.

Discuss With Your Physician

Anyone participating in a clinical trial should know as much as possible about what is being studied, what risks are involved and what potential benefits may be gained before deciding to enroll.  If you are interested in participating in a clinical trial, please talk to your physician first.

Print Friendly, PDF & Email

Print, save, or email this page to your physician to discuss at your next visit.

Be sure to have National Trial Reference Number NCT01906385 available.

Contact A Trial Coordinator

A trial coordinator is a specialized researcher who supports the management and coordination of clinical research studies.  If you are interested in participating in a clinical trial, you may call a trial coordinator directly at one of the trial locations below.

UT Health Science Center
San Antonio

Epp Goodwin

Morgan Seekatz

UT Southwestern Medical Center

Tiffany Thomas

Omar Raglan

UT MD Anderson Cancer Center

Summer Stovall

Contact Us


January 18, 2023

Plus Therapeutics Announces First Patient Dosed in ReSPECT-GBM Phase 2b Trial of Rhenium (186Re) Obisbemeda for Treatment of Recurrent Glioblastoma

Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system cancers, today announced that the first patient has been dosed in the ReSPECT-GBM Phase 2b dose expansion clinical trial evaluating rhenium (186Re) obisbemeda for the treatment of recurrent glioblastoma (GBM).

November 19, 2022

Plus Therapeutics Provides Updates on ReSPECT™ Clinical Trials at the 27th Annual Scientific Meeting and Education Day of the Society for Neuro-Oncology

ReSPECT-GBM clinical trial of rhenium (186Re) obisbemeda in recurrent glioblastoma continues to demonstrate safety and overall survival correlates with radiation dose to tumor.  ReSPECT-GBM Phase 2 trial enrollment has begun.

September 12, 2022

Plus Therapeutics Presents Positive Phase 1 Data from ReSPECT-GBM Clinical Trial at the European Society for Medical Oncology Congress 2022

August 13, 2022

Plus Therapeutics Presents Positive Data from Ongoing ReSPECT™ Clinical Trials at the Annual Conference on CNS Clinical Trials and Brain Metastases

June 13, 2022

Plus Therapeutics Reports Positive Clinical Outcomes from ReSPECT-GBM Trial at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2022 Annual Meeting

November 18, 2021

Plus Therapeutics Announces Positive Interim Data from ReSPECT™-GBM Phase 1 Clinical Trial at the 2021 Society for Neuro-Oncology Annual Meeting

August 21, 2021

Plus Therapeutics Announces Presentation of Data from the ReSPECT™-GBM Trial and Plans for Treating Pediatric Brain Cancer

July 22, 2021

Plus Successfully Treats First Patient in Latest Dosing Cohort in ReSPECT™-GBM Trial

June 16, 2021

Plus Therapeutics Announces DSMB Approval to Proceed into Eighth Cohort in ReSPECT™ Glioblastoma Trial

December 15, 2020

Plus Therapeutics Completes Sixth Dosing Cohort in ReSPECT™ Glioblastoma Trial

December 1, 2020

Plus Therapeutics Expands ReSPECT™ Clinical Trial to MD Anderson Cancer Center

November 19, 2020

Plus Therapeutics Announces Positive Interim Data from ReSPECT™ Phase 1 Clinical Trial in Recurrent Glioblastoma

November 13, 2020

Plus Therapeutics Announces Webinar to Present ReSPECT™ Glioblastoma Clinical Trial Update

October 29, 2020

Plus Therapeutics Announces Initiation of Final Cohort of ReSPECT™ Glioblastoma Trial

October 2, 2020

Plus Therapeutics Announces Brain Cancer Clinical Advisory Team

October 1, 2020

ReSPECT Glioblastoma Clinical Trial Data to be Presented at 2020 Society for Neuro-Oncology Annual Meeting

September 15, 2020

Plus Therapeutics Receives Fast Track Designation From FDA for Its Novel Glioblastoma Treatment

September 1, 2020

Plus Therapeutics, Inc. receives FDA Orphan Drug Designation for its Novel Glioblastoma Treatment

July 28, 2020

Plus Therapeutics Completes Fifth Dose Escalation Cohort of the ReSPECT™ Glioblastoma Clinical Trial and Expands Trial Sites

May 12, 2020

Plus Therapeutics Announces Patient-Focused Presentation Supporting Brain Tumor Awareness Month



Copyright © 2022 Plus Therapeutics, Inc. All rights reserved. ReSPECT is a trademark of Plus Therapeutics, Inc. This website is intended for a U.S. audience only.